Table 3.

Patients with hyperinsulinism receiving octreotide that had a serious adverse event (n = 12)

	Gestational age	Birth weight	Age in weeks at admission	SAE specification	SAE days after admission	SAE days after octreotide	Octreotide dose (mcg/kg)	Times per day administered	Route of administration	Days administered	Cause of death
1	—	—	69.6	Complications of G-tube placement	24	23	5.95	2	Intravenous	14	N/A
2	—	—	30.45	DVT right basilic vein, treated Lovenox	6	3	3.06	1	Intravenous	1	N/A
3	37	—	7.29	Hyperglycemia	11	10	4.52	3	Intravenous	5	N/A
4	38		1.29	Hyperglycemia (8 days before admission), Hypoglycemia (2 days after admission)	2	1	1.66	3	Intravenous	12	N/A
5	36.6	3.9	4.35	Hypoglycemia	37	37	3.8	4	Subcutaneous + intravenous	60	N/A
6	—	—	4.35	Hypoglycemic seizure after octreotide stopped	7	7	3.18	3	Subcutaneous + intravenous	8	N/A
7	32	3.54	4	Hypoxia	66	65		4	Intravenous	3	Cardiorespiratory failure 2° to cardiomyopathy, chronic lung disease, and sepsis
8	—	4.63	0.86	Hypoxia	0	0	3.71	4	Intravenous	2	N/A
9	36	—	43.5	Intussusception	—	—	3.9	3	Subcutaneous	5	N/A
10	40	—	48	Lipohypertrophy, bilateral thighs injection sites	24	16	3.5	3	Subcutaneous	15	N/A
11	39	3.5	2.1	NEC, hypoxia, hypotension, hyperglycemia	3	3	4	3	Subcutaneous	3	NEC
12			34.8	Thrombosis, right leg site of old line	2	2	3.04	2	Intravenous	4	N/A

—, information not recorded; SAE, serious adverse event; DVT, deep vein thrombosis; NEC, necrotizing enterocolitis; N/A, not applicable.